

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:1034333 CAPLUS Full-text  
 DN 145:397557  
 TI Preparation of tartaric acid salts of a dipeptidyl peptidase-IV inhibitor  
 IN Song, Zhiguo J.; Zhang, Fei; Shultz, Rebecca Leigh  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 28pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006104997	A2	20061005	WO 2006-US11064	20060324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-665997P P 20050329

AB Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as Type 2 diabetes. The invention also relates to crystalline anhydrate forms of the tartaric acid salts as well as a process for their preparation, pharmaceutical compns. containing these novel forms and methods of use for the treatment of Type 2 diabetes.

IT 911223-30-8P 911301-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazepinone tartrate salts for treating Type 2 diabetes)

RN 911223-30-8 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)-, (3R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 892144-12-6

CMF C17 H19 F6 N3 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



RN 911301-54-7 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)-, (3R)-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 892144-12-6

CMF C17 H19 F6 N3 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 133-37-9


CMF C4 H6 O6

Relative stereochemistry.




IT 892113-81-4P  
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of diazepinone tartrate salts for treating Type 2 diabetes)  
 RN 892113-81-4 CAPLUS  
 CN Carbamic acid, [(1R)-3-[(2R)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 892113-88-1P 892113-96-1P 892114-03-3P  
 911223-29-5P  
 RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of diazepinone tartrate salts for treating Type 2 diabetes)  
 RN 892113-88-1 CAPLUS  
 CN Carbamic acid, [(1R)-3-[(2S)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 892113-96-1 CAPLUS

CN Carbamic acid, [(1S)-3-[(2R)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 892114-03-3 CAPLUS

CN Carbamic acid, [(1S)-3-[(2S)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911223-29-5 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)-, (3S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 911223-28-4

CMF C17 H19 F6 N3 O2

Absolute stereochemistry.




CM 2

CRN 147-71-7

CMF C4 H6 O6

Absolute stereochemistry..



IT 911223-26-2F

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazepinone tartrate salts for treating Type 2 diabetes and crystal structure)

RN 911223-26-2 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)-, (3R)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 892144-12-6

CMF C17 H19 F6 N3 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 147-71-7

CMF C4 H6 O6



Absolute stereochemistry.



L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:603862 CAPLUS Full-text  
DN 145:63148

TI Process for the preparation of chiral  $\beta$ -amino acid derivatives by  
asymmetric hydrogenation  
IN Biftu, Tesfaye; Song, Zhiguo J.; Zhang, Fei; Rosner, Thorsten; Hansen,  
Karl; Armstrong, Joseph D., III  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 41 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065826	A2	20060622	WO 2005-US45096	20051212
	WO 2006065826	A3	20061005		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-636223P	P	20041215		
	US 2005-659165P	P	20050307		
OS	MARPAT 145:63148				
GI					




AB The invention relates to a process for the efficient preparation of enantiomerically enriched  $\beta$ -amino acid derivs. I (Ar is Ph which may be substituted by halogen, CF<sub>3</sub> or CF<sub>3</sub>O; R is alkyl or fluoroalkyl) which are inhibitors of dipeptidyl peptidase-IV. The process comprises enantioselective hydrogenation of prochiral  $\beta$ -amino acrylic acid derivative II in the presence of a transition metal precursor complexed with a chiral ferrocenyl diphosphine ligand with in situ protection of the primary amine product. Thus, acrylic acid derivative II (Ar is 2,4,5-F<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, R is CF<sub>3</sub>CH<sub>2</sub>) (preparation given) was hydrogenated in the presence of chloro(1,5-cyclooctadiene)rhodium(I) dimer, (R,S)-t-Bu Josiphos, and Boc<sub>2</sub>O in MeOH to give I.HCl, following separation of isomers and deprotection.

IT 892114-11-3P  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of chiral  $\beta$ -amino acid derivs. by asym. hydrogenation of prochiral  $\beta$ -amino acryloyldiazepinones)

RN 892114-11-3 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT 892113-81-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chiral  $\beta$ -amino acid derivs. by asym. hydrogenation of prochiral  $\beta$ -amino acryloyldiazepinones)

RN 892113-81-4 CAPLUS

CN Carbamic acid, [(1R)-3-[(2R)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 892113-88-1P 892113-96-1P 892114-03-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of chiral  $\beta$ -amino acid derivs. by asym. hydrogenation of prochiral  $\beta$ -amino acryloyldiazepinones)

RN 892113-88-1 CAPLUS

CN Carbamic acid, [(1R)-3-[(2S)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 892113-96-1 CAPLUS

CN Carbamic acid, [(1S)-3-[(2R)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 892114-03-3 CAPLUS

CN Carbamic acid, [(1S)-3-[(2S)-hexahydro-3-oxo-2-(2,2,2-trifluoroethyl)-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







App's

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:120662 CAPLUS Full-text  
 DN 142:219315  
 TI Preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors  
 IN Biftu, Tesfaye; Liang, Gui-Bai; Feng, Danqing Dennis; Weber, Ann E.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011581	A2	20050210	WO 2004-US24052	20040727
	WO 2005011581	A3	20050428		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004261186	A1	20050210	AU 2004-261186	20040727
	CA 2533893	AA	20050210	CA 2004-2533893	20040727
	EP 1651623	A2	20060503	EP 2004-779221	20040727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	US 2006211682	A1	20060921	US 2006-566235	20060127
PRAI	US 2003-491606P	P	20030731		
	WO 2004-US24052	W	20040727		
OS	CASREACT 142:219315; MARPAT 142:219315				
GI					



AB Title compds. I [Ar = Ph substituted with one to five R3; R3 = H, halo, cyano, etc.; R1 = H, (un)substituted alkyl, (CH2)naryl etc., wherein aryl is (un)substituted with one to five substituents independently selected from halo, cyano, hydroxy, etc.; R4, R6, R10 = H, cyano, carboxy, etc.; R8 = halo, hydroxy, R4; R5, R7, R11 = H, alkyl; further details on R1, R7 are given; R9 = H, hydroxy, halo, etc. with the proviso that at least one of R6, R7, R8 and R9 is not hydrogen] and their pharmaceutically acceptable salts were prepared For

example, acylation of (3R,7R)-3,7-dimethyl-1,4-diazepan-2-one with (3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid, e.g., prepared from (2S)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine in 4 steps, using iso-Bu chloroformate followed by treatment with HCl afforded compound II hydrochloride. Compds. I are claimed useful for the treatment of

hyperglycemia, type 2 diabetes, etc. (no data).

IT 842103-62-2P 842103-63-3P 842103-64-4P  
842103-65-5P 842103-66-6P 842103-67-7P  
842103-68-8P 842103-69-9P 842103-70-2P  
842103-71-3P 842103-72-4P 842103-73-5P  
842103-74-6P 842103-75-7P 842103-76-8P  
842103-77-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors for treatment of hyperglycemia, type 2 diabetes, etc.)

RN 842103-62-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,7-dimethyl-, monohydrochloride, (3R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-63-3 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2-pyridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 842103-64-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-7-[(2-fluorophenyl)methyl]hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-65-5 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-7-[(2-fluorophenyl)methyl]hexahydro-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-66-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 842103-67-7 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 842103-68-8 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 842103-69-9 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[(2-methylphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-70-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[[2-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-71-3 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, monohydrochloride, (3R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-72-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, monohydrochloride, (3R,6R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-73-5 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-6-methyl-, monohydrochloride, (3R,6S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-74-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-6-methyl-, monohydrochloride, (3R,6R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-75-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-6-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride, (3R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 842103-76-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-6-methyl-3-(2,2,2-trifluoroethyl)-, monohydrochloride, (3R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 842103-77-9 CAPLUS  
 CN 5H-Pyrrolo[1,2-d][1,4]diazepin-5-one, 3-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]octahydro-4-methyl-, (4R,9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 842103-78-0 842103-79-1 842103-80-4  
 842104-13-6 842104-14-7 842104-15-8  
 842104-16-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors  
 for treatment of hyperglycemia, type 2 diabetes, etc.)  
 RN 842103-78-0 CAPLUS  
 CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-7-methyl-, (3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842103-79-1 CAPLUS  
 CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[(2-methylphenyl)methyl]-, (3R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 842103-80-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-[[2-(trifluoromethyl)phenyl]methyl]-, (3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-13-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,7-dimethyl-, (3R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-14-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-15-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3,6-dimethyl-, (3R,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-16-9 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-7-methyl-3-(2,2,2-trifluoroethyl)-, (3R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 842104-11-4P 842104-12-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hexahydrodiazepinones as dipeptidyl peptidase IV inhibitors for treatment of hyperglycemia, type 2 diabetes, etc.)

RN 842104-11-4 CAPLUS

CN Carbamic acid, [(1R)-3-[(2R,5R)-hexahydro-2,5-dimethyl-3-oxo-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 842104-12-5 CAPLUS

CN Carbamic acid, [(1R)-3-[(2R,6S)-hexahydro-2,6-dimethyl-3-oxo-1H-1,4-diazepin-1-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:368864 CAPLUS Full-text  
DN 140:391494

TI Preparation of  $\beta$ -amino heterocyclic dipeptidyl peptidase inhibitors  
for the treatment or prevention of diabetes

IN Biftu, Tesfaye; Liang, Gui-Bai; Qian, Xiaoxia; Weber, Ann E.; Feng,  
Dangqing Dennis

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 74 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037169	A2	20040506	WO 2003-US32222	20031014
	WO 2004037169	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2502269	AA	20040506	CA 2003-2502269	20031014
	AU 2003298596	A1	20040513	AU 2003-298596	20031014
	EP 1556362	A2	20050727	EP 2003-796347	20031014
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003015381	A	20050823	BR 2003-15381	20031014
	CN 1705647	A	20051207	CN 2003-80101617	20031014
	JP 2006510608	T2	20060330	JP 2004-546826	20031014
	US 2004254167	A1	20041216	US 2004-501059	20040709
	US 7101871	B2	20060905		
	ZA 2005002162	A	20060222	ZA 2005-2162	20050315
	NO 2005002380	A	20050616	NO 2005-2380	20050513
PRAI	US 2002-419703P	P	20021018		
	WO 2003-US32222	W	20031014		
OS	MARPAT 140:391494				
GI					



AB The invention relates to diazepinone  $\beta$ -amino acid derivs. I [Ar is substituted phenyl; R1 is (un)substituted alkyl, (CH<sub>2</sub>)<sub>0-2</sub>-aryl, -heteroaryl, -heterocyclyl or -cycloalkyl; R4, R5 are H, cyano, carboxy, carbalkoxy, (un)substituted alkyl, (CH<sub>2</sub>)<sub>0-2</sub>-aryl, etc.; R6, R9 are H or alkyl] which are inhibitors of the

dipeptidyl peptidase-IV enzyme (DP-IV inhibitors) and are useful in the treatment or prevention of diseases, e.g., type 2 diabetes, in which DP-IV enzyme is involved. Thus, diazepam II was prepared by a multistep procedure in which intermediate Me N-(3-aminopropyl)-N-(tert-butoxycarbonyl)-D-alaninate underwent Me3Al-catalyzed cyclization to tert-Bu (2R)-hexahydro-2-methyl-3-oxo-1H- 1,4-diazepine-1-carboxylate.

IT 685857-73-2P 685857-75-4P 685857-77-6P  
 685857-79-8P 685857-81-2P 685857-83-4P  
 685857-86-7P 685857-89-0P 685857-92-5P  
 685857-94-7P 685857-96-9P 685857-98-1P  
 685858-00-8P 685858-02-0P 685858-04-2P  
 685858-06-4P 685858-08-6P 685858-10-0P  
 685858-12-2P 685858-14-4P 685858-16-6P  
 685858-18-8P 685858-20-2P 685858-22-4P  
 685858-24-6P 685858-26-8P 685858-28-0P  
 685858-30-4P 685858-32-6P 685858-34-8P  
 685858-36-0P 685858-38-2P 685858-40-6P  
 685858-42-8P 685858-44-0P 685858-46-2P  
 685858-48-4P 685858-50-8P 685858-52-0P  
 685858-54-2P 685858-56-4P 685858-58-6P  
 685858-60-0P 685858-62-2P 685858-64-4P  
 685858-66-6P 685858-68-8P 685858-70-2P  
 685858-72-4P 685858-74-6P 685858-76-8P  
 685858-78-0P 685858-80-4P 685858-82-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazepam  $\beta$ -amino acid derivs. as dipeptidyl peptidase inhibitors for treatment or prevention of diabetes)

RN 685857-73-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-, monohydrochloride, (3R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-75-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-77-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-(phenylmethyl)-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-79-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-81-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-1-(1,1-dimethylethyl)hexahydro-3-methyl-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 685857-83-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 685857-86-7 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(1-oxido-2-pyridinyl)methyl]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-85-6

CMF C21 H23 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 685857-89-0 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(1-oxido-3-pyridinyl)methyl]-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-88-9

CMF C21 H23 F3 N4 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 685857-92-5 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(1H-pyrazol-1-ylmethyl)-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 685857-91-4

CMF C19 H22 F3 N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 685857-94-7 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685857-96-9 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-(cyclopropylmethyl)hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685857-98-1 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1,3-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-00-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]-1-ethylhexahydro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-02-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-

trifluorophenyl)butyl]-1-cyclopropylhexahydro-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-04-2 CAPLUS

CN 1H-1,4-Diazepine-1-acetic acid, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-06-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-(2-hydroxyethyl)-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-08-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-10-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-12-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]-3-ethylhexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-14-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(hydroxymethyl)-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-16-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2-fluorophenyl)-1-oxobutyl]hexahydro-1-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-18-8 CAPLUS


CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(3,4-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-20-2 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-[(phenylmethoxy)methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 685858-22-4 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-ethylhexahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-24-6 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-26-8 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(3,4-difluorophenyl)-1-oxobutyl]hexahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 685858-28-0 CAPLUS  
CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-30-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[3-(trifluoromethoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-32-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-(2-methylpropyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-34-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[[3,5-bis(trifluoromethyl)phenyl]methyl]hexahydro-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-36-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-38-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-40-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-chlorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-42-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-44-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,5-dimethylphenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-46-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-48-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(1,1'-biphenyl)-2-ylmethyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-50-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,5-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-52-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-54-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-56-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,3-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-58-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 685858-60-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-1-propyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 685858-62-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-64-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2-fluorophenyl)methyl]hexahydro-1-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 685858-66-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-

trifluorophenyl)butyl]hexahydro-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-68-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-3-[(2,6-difluorophenyl)methyl]hexahydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-70-2 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-72-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-methyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685858-74-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-1-methyl-3-(phenylmethyl)-, (3R)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 685858-76-8 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-3-[[4-(trifluoromethoxy)phenyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-78-0 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-1-(1,1-dimethylethyl)hexahydro-3-methyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685858-80-4 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]hexahydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 685858-82-6 CAPLUS

CN 2H-1,4-Diazepin-2-one, 4-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]hexahydro-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l2; d his; log y  
L2 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 18:05:26 ON 11 NOV 2006)

FILE 'REGISTRY' ENTERED AT 18:05:41 ON 11 NOV 2006

L1 STRUCTURE UPLOADED  
L2 QUE L1  
L3 6 S L2  
L4 105 S L2 FUL

FILE 'CAPLUS' ENTERED AT 18:06:26 ON 11 NOV 2006

L5 4 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.36	188.51
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 18:07:28 ON 11 NOV 2006